In recent years, a number of drugs have emerged that have significant cardio-renal protective effects in patients with diabetes, and a typical example is sodium-glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonist (GLP-1RA), and nonsteroidal mineralocorticoid receptor antagonist, finerenone
Liraglutide, a GLP-1 analog, emerges as a promising therapeutic agent in this context
Choose retatrutide if the research question specifically targets hepatic steatosis, fat oxidation, or the glucagon-axis contribution to energy expenditure, and if you can tolerate a thinner Phase 3 evidence base and longer titration window
If you cannot keep fluids down and have not had a bowel movement in several days, seek emergency care
Other health risks include: Pancreatitis: Some studies suggest a possible link between GLP-1s and inflammation of the pancreas, though the risk appears to be low
If a platform can't answer them, that tells you something too